Biocon Completes Phase I Trial For Lantus Biosimilar, As Speculation Builds On Deal For Oral Insulin
This article was originally published in PharmAsia News
Executive Summary
A steadily developing pipeline – including a biosimilar of Sanofi’s blockbuster diabetes therapy Lantus – is starting to bear fruit. Meanwhile, speculation is building that Biocon is close to partnering its oral insulin IN-105, with Bristol-Myers Squibb as a rumored suitor.
You may also be interested in...
With Bristol/AstraZeneca In Driver’s Seat, GLP-1 Race Takes A Turn
Bristol-Myers and AstraZeneca’s acquisition of Amylin as part of a 50-50 collaboration brings a big new player into the fast-growing GLP-1 class, which is emerging as a key component of treatment in the large, but highly competitive Type 2 diabetes market.
India's Biocon Says Primary Endpoints Set For Oral Insulin May Have Been "Harsh"; Reinforces Goal To Develop Drug With Global Partner
MUMBAI - Indian biotechnology firm Biocon has reinforced its ambitions to bring to market an orally delivered insulin and said it stays firmly on track as it found several "unique and positive" takeaways from its recently concluded Phase III clinical trials in India
Indian Investors Turn Cautious On Compliance Concerns
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.